Search

Displaying results 5451 - 5460 of 10000 in total
  1. Drug

    Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11046
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  3. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable

  4. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Ruxolitinib Combinations in Myelofibrosis Patients). … Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

    Synonyms: 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluorobenzamide, Benzamide, 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluoro-
  5. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. … In some cases, the cells are created from blood samples of patients who have recovered from viral infections.

  6. Drug

    Indisulam

    go.drugbank.com/drugs/DB06370
    Investigational

  7. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients

  8. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  9. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).

  10. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.